Caplin Point Laboratories Limited

NSE CAPLIPOINT.NS

Caplin Point Laboratories Limited Gross Profit Margin for the year ending March 31, 2024: 54.91%

Caplin Point Laboratories Limited Gross Profit Margin is 54.91% for the year ending March 31, 2024, a 0.22% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Caplin Point Laboratories Limited Gross Profit Margin for the year ending March 31, 2023 was 54.78%, a -1.52% change year over year.
Caplin Point Laboratories Limited Gross Profit Margin for the year ending March 31, 2022 was 55.63%, a 1.74% change year over year.
Caplin Point Laboratories Limited Gross Profit Margin for the year ending March 31, 2021 was 54.68%, a 5.65% change year over year.
Caplin Point Laboratories Limited Gross Profit Margin for the year ending March 31, 2020 was 51.75%, a -6.26% change year over year.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

NSE: CAPLIPOINT.NS

Caplin Point Laboratories Limited

CEO	Dr. Sridhar Ganesan
IPO Date	June 23, 2014
Location	India
Headquarters	Ashvich Tower
Employees	3,406
Sector	Health Care
Industries Pharmaceuticals Consumer Packaged Goods Cosmetics

Description

Caplin Point Laboratories Limited develops, produces, markets, and exports generic pharmaceutical formulations and branded products in India. The company provides liquid and lyophilized injections, ophthalmic products, tablets, liquid orals, capsules, softgel capsules, suppositories and ovules, powder for injection, dry syrups, topicals, inhalers, IV infusions, lyophilized products, branded products, dermo cosmetics, and other products. It also operates QueTenX, an e-commerce website. The company was incorporated in 1990 and is headquartered in Chennai, India.

Key trends

Past 5 years